ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Psychiatry

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,016Medicare Part D Prescriptions Filled, Including Refills

Rank: 7 out of 1478

$2.32M Total Retail Price of All Prescriptions

Rank: 1 out of 1478

738 Patients Receiving at Least One Drug in Part D
24%Patients 65 Years and Older
74% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 738 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

3% of this provider’s 738 patients filled at least one prescription for a schedule three drug, compared to an average of 0%.

Risky Drugs to Seniors

0% of this provider’s 2,065 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 3%.

Brand Name Drugs

38% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$232 was the average price of a prescription from this provider, compared to $124 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
LAMOTRIGINE 864 161 1 15
CYMBALTA 528 130 2 13
OLANZAPINE 481 145 3 9
RISPERIDONE 307 17 4 1
FLUOXETINE HCL 303 39 5 12
SERTRALINE HCL 287 63 6 3
ABILIFY 266 15 7 5
LATUDA 263 22 8 58
GABAPENTIN 234 62 9 24
VENLAFAXINE HCL ER 226 84 10 20
BUPROPION XL 208 54 11 16
LAMICTAL 203 18 12 96
DIVALPROEX SODIUM ER 197 30 13 14
SEROQUEL XR 194 30 14 25
NAMENDA 190 150 15 26
QUETIAPINE FUMARATE 189 34 16 7
ESCITALOPRAM OXALATE 174 31 17 18
PRISTIQ ER 172 94 18 36
DONEPEZIL HCL 168 79 19 28
SYMBYAX 165 34 10 20 110
TOPIRAMATE 158 0 21 33
SUBOXONE 157 13 22 55
ARICEPT 141 89 23 94
CITALOPRAM HBR 137 46 24 6
MIRTAZAPINE 128 58 25 11
ZIPRASIDONE HCL 128 0 25 31
ZYPREXA 118 0 27 38
ZOLPIDEM TARTRATE 115 13 28 2
PROPRANOLOL HCL 114 14 29 41
TRAZODONE HCL 112 36 30 8
CLOZAPINE 110 13 31 10
PAROXETINE HCL 108 32 32 19
SAPHRIS 107 0 33 72
LITHIUM CARBONATE 105 23 34 21
DIVALPROEX SODIUM 99 21 35 17
LAMICTAL ODT 99 0 10 35 145
LYRICA 98 0 37 88
BUSPIRONE HCL 96 28 38 23
SEROQUEL 90 16 39 27
LEVETIRACETAM 78 18 40 84
NUEDEXTA 69 13 41 113
OLANZAPINE-FLUOXETINE HCL 68 0 10 42 164
ZONISAMIDE 68 13 42 164
AMPHETAMINE SALT COMBO 65 0 S2 44 61
FANAPT 63 0 45 97
EXELON 63 50 45 35
CARBAMAZEPINE 62 0 47 50
LEXAPRO 58 16 48 30
OXCARBAZEPINE 57 0 49 40
OLANZAPINE ODT 56 12 50 63
NUVIGIL 51 0 51 189
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 9, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.